Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 5 5 W ELECTROLYTES.
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 5.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 4.25% w/ Dextrose 25% provides amino acids for protein synthesis and dextrose as a caloric source, supporting nitrogen balance and energy requirements in parenteral nutrition.
TRAVASOL 5.5% W/ ELECTROLYTES is a parenteral nutritional solution providing amino acids and electrolytes. Amino acids serve as substrates for protein synthesis, while electrolytes maintain osmotic balance and support cellular functions. The solution bypasses gastrointestinal absorption, directly entering the bloodstream.
Adults: 1-3 L/day intravenously through central line. Infusion rate initially 50-100 mL/hour, titrate to achieve protein and calorie requirements.
Intravenous infusion: 25-40 mL/kg/day (1.5-2.2 g amino acids/kg/day) as total parenteral nutrition; rate adjusted based on metabolic and clinical response.
None Documented
None Documented
Amino acids: 10-30 min (rapid distribution). Dextrose: glucose half-life ~1.5-2 h in euglycemia; prolonged in renal impairment. Clinically, continuous infusion maintains steady state without significant accumulation.
2–3 hours for infused amino acids; clinical context: rapid clearance in normal renal function, prolonged in renal impairment.
Amino acids are metabolized; nitrogen waste is excreted renally as urea. Dextrose is metabolized to CO2 and water. Renal excretion accounts for >95% of nitrogen elimination. Minimal biliary/fecal elimination.
Renal, >95% as amino acids and metabolites; negligible biliary/fecal.
Category C
Category C
Amino Acid Solution
Amino Acid Solution